Neuren Pharmaceuticals Ltd., of Sydney, Australia, was granted U.S. Patent No. 7,041,314, titled "GPE Analogs and Peptidomimetics," which describes NNZ-2566, a neuroprotective analogue of Glypromate.

Oncolytics Biotech Inc., of Calgary, Alberta, was granted U.S. Patent No. 7,049,127, titled "Method of Producing Infectious Reovirus." The company also received U.S. Patent No. 7,052,832, titled "Methods for the Treatment of Cellular Proliferative Disorders," which describes the methods of identifying cells' susceptibility to reovirus infection.

Ortec International Inc., of New York, received a notice of allowance for a patent, titled "Novel Haptotactic Peptides," relating to its Haptides technology platform.

OxiGene Inc., of Waltham, Mass., was issued U.S. Patent No. 7,037,906, titled "Methods for Modulating Tumor Growth and Metastasis." It covers the use and administration of Combretastatin A4P in combination with paclitaxel in cancer.

Pharsight Corp., of Mountain View, Calif., was issued U.S. Patent No. 7,043,415, covering interactively building pharmacokinetic and pharmacodynamic models using graphical interface.

Phylonix Pharmaceuticals Inc., of Cambridge, Mass., received U.S. Patent No. 7,041,276, titled "Methods of Screening Agents for Activity Using Teleosts," which covers a method of drug screening for angiogenesis in zebrafish.

Predix Pharmaceuticals Holdings Inc., of Lexington, Mass., received U.S. Patent No. 7,030,240 B2, which includes claims to the composition of matter, synthesis and use of 5-HT receptor antagonists in physiological conditions associated with serotonin action. This covers PRX-08066, a 5-HT2B antagonist.

Salix Pharmaceuticals Ltd., of Raleigh, N.C., received U.S. Patent No. 7,045,620, titled "Polymorphous Forms of Rifaximin Processes for Their Production and Use Thereof in the Medicinal Preparations," which extends coverage for rifaximin, marketed in the U.S. as Xifaxan.

Sentigen Holding Corp., of Phillipsburg, N.J., received U.S. Patent No. 7,049,076, titled "Method for Assaying Protein-Protein Interaction," covering the core methods underlying the company's Tango Assay System. Sentigen also received U.S. Patent No. 7,045,281, titled "Method for Using Division Arrested Cells in Screening Assays," covering the generation and application of division arrested assay ready cells in drug discovery.